Skip to main content

SPIRIVA RESPIMAT

LAMA SMI

Tiotropium bromide · Boehringer Ingelheim

Clinical Reference · Data reviewed June 2026

Active Medication & Mechanism

  • Tiotropium bromide monohydrate LAMA
    1.25 mcg or 2.5 mcg per actuation

    Long-acting muscarinic antagonist. Provides 24-hour bronchodilation by blocking M3 muscarinic receptors on airway smooth muscle with very slow receptor dissociation kinetics.

FDA-Approved Dosing — Strength × Indication

1.25 mcg 2 puffs (2.5 mcg total) once daily → 2.5 mcg
Asthma FDA Approved
Add-on maintenance treatment of asthma in adults already on ICS. Not a substitute for ICS.
COPD Not Approved
The 1.25 mcg strength is NOT indicated for COPD — use the 2.5 mcg strength.
2.5 mcg 2 puffs (5 mcg total) once daily → 5 mcg
Asthma
COPD FDA Approved
Long-term, once-daily maintenance treatment of bronchospasm in COPD. Also reduces exacerbations.

All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling

Not a rescue inhaler. Onset too slow for rescue. Use a SABA.

Related Inhalers

For educational reference by healthcare professionals. Not medical advice and not for use in clinical decision-making. This workspace is not a substitute for clinical judgement, prescribing information, or product monographs — always verify doses and indications against the most current labelling. If you are a patient, do not use this site to make medication decisions — speak with your clinician.

Device images are original illustrations for identification aid only — actual devices and packaging may differ. This site is not affiliated with or endorsed by any pharmaceutical manufacturer. Clinical data last reviewed: June 2026.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved